Revertant mosaicism for family mutations is not observed in BRCA1/2 phenocopies

Jacopo Azzollini, Chiara Pesenti, Luca Ferrari, Laura Fontana, Mariarosaria Calvello, Bernard Peissel, Giorgio Portera, Silvia Tabano, Maria Luisa Carcangiu, Paola Riva, Monica Miozzo, Siranoush Manoukian

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

In BRCA1/2 families, early-onset breast cancer (BrCa) cases may be also observed among non-carrier relatives. These women are considered phenocopies and raise difficult counselling issues concerning the selection of the index case and the residual risks estimate in negative family members. Few studies investigated the presence of potential genetic susceptibility factors in phenocopies, mainly focussing on BrCa-associated single-nucleotide polymorphisms. We hypothesized that, as for other Mendelian diseases, a revertant somatic mosaicism, resulting from spontaneous correction of a pathogenic mutation, might occur also in BRCA pedigrees. A putative low-level mosaicism in phenocopies, which has never been investigated, might be the causal factor undetected by standard diagnostic testing. We selected 16 non-carriers BrCa-affected from 15 BRCA1/2 families, and investigated the presence of mosaicism through MALDI-TOF mass spectrometry. The analyses were performed on available tumour samples (7 cases), blood leukocytes, buccal mucosa and urine samples (2 cases) or on blood only (7 cases). In one family (n.8), real-time PCR was also performed to analyse the phenocopy and her healthy parents. On the 16 phenocopies we did not detect the family mutations neither in the tumour, expected to display the highest mutation frequency, nor in the other analysed tissues. In family 8, all the genotyping assays did not detect mosaicism in the phenocopy or her healthy parents, supporting the hypothesis of a de novo occurrence of the BRCA2 mutation identified in the proband. These results suggest that somatic mosaicism is not likely to be a common phenomenon in BRCA1/2 families. As our families fulfilled high-risk selection criteria, other genetic factors might be responsible for most of these cases and have a significant impact on risk assessment in BRCA1/2 families. Finally, we found a de novo BRCA2 mutation, suggesting that, although rare, this event should be taken into account in the evaluation of high-risk families.

Original languageEnglish
Article numbere0171663
JournalPLoS One
Volume12
Issue number2
DOIs
Publication statusPublished - Feb 1 2017

Fingerprint

Mosaicism
mutation
Mutation
Tumors
breast neoplasms
Blood
Polymorphism
Risk assessment
Mass spectrometry
Assays
Nucleotides
neoplasms
risk estimate
counseling
Tissue
matrix-assisted laser desorption-ionization mass spectrometry
selection index
blood
Breast Neoplasms
selection criteria

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Revertant mosaicism for family mutations is not observed in BRCA1/2 phenocopies. / Azzollini, Jacopo; Pesenti, Chiara; Ferrari, Luca; Fontana, Laura; Calvello, Mariarosaria; Peissel, Bernard; Portera, Giorgio; Tabano, Silvia; Carcangiu, Maria Luisa; Riva, Paola; Miozzo, Monica; Manoukian, Siranoush.

In: PLoS One, Vol. 12, No. 2, e0171663, 01.02.2017.

Research output: Contribution to journalArticle

Azzollini, J, Pesenti, C, Ferrari, L, Fontana, L, Calvello, M, Peissel, B, Portera, G, Tabano, S, Carcangiu, ML, Riva, P, Miozzo, M & Manoukian, S 2017, 'Revertant mosaicism for family mutations is not observed in BRCA1/2 phenocopies', PLoS One, vol. 12, no. 2, e0171663. https://doi.org/10.1371/journal.pone.0171663
Azzollini, Jacopo ; Pesenti, Chiara ; Ferrari, Luca ; Fontana, Laura ; Calvello, Mariarosaria ; Peissel, Bernard ; Portera, Giorgio ; Tabano, Silvia ; Carcangiu, Maria Luisa ; Riva, Paola ; Miozzo, Monica ; Manoukian, Siranoush. / Revertant mosaicism for family mutations is not observed in BRCA1/2 phenocopies. In: PLoS One. 2017 ; Vol. 12, No. 2.
@article{095ebe80e37d40eea89c2de6a3190cd8,
title = "Revertant mosaicism for family mutations is not observed in BRCA1/2 phenocopies",
abstract = "In BRCA1/2 families, early-onset breast cancer (BrCa) cases may be also observed among non-carrier relatives. These women are considered phenocopies and raise difficult counselling issues concerning the selection of the index case and the residual risks estimate in negative family members. Few studies investigated the presence of potential genetic susceptibility factors in phenocopies, mainly focussing on BrCa-associated single-nucleotide polymorphisms. We hypothesized that, as for other Mendelian diseases, a revertant somatic mosaicism, resulting from spontaneous correction of a pathogenic mutation, might occur also in BRCA pedigrees. A putative low-level mosaicism in phenocopies, which has never been investigated, might be the causal factor undetected by standard diagnostic testing. We selected 16 non-carriers BrCa-affected from 15 BRCA1/2 families, and investigated the presence of mosaicism through MALDI-TOF mass spectrometry. The analyses were performed on available tumour samples (7 cases), blood leukocytes, buccal mucosa and urine samples (2 cases) or on blood only (7 cases). In one family (n.8), real-time PCR was also performed to analyse the phenocopy and her healthy parents. On the 16 phenocopies we did not detect the family mutations neither in the tumour, expected to display the highest mutation frequency, nor in the other analysed tissues. In family 8, all the genotyping assays did not detect mosaicism in the phenocopy or her healthy parents, supporting the hypothesis of a de novo occurrence of the BRCA2 mutation identified in the proband. These results suggest that somatic mosaicism is not likely to be a common phenomenon in BRCA1/2 families. As our families fulfilled high-risk selection criteria, other genetic factors might be responsible for most of these cases and have a significant impact on risk assessment in BRCA1/2 families. Finally, we found a de novo BRCA2 mutation, suggesting that, although rare, this event should be taken into account in the evaluation of high-risk families.",
author = "Jacopo Azzollini and Chiara Pesenti and Luca Ferrari and Laura Fontana and Mariarosaria Calvello and Bernard Peissel and Giorgio Portera and Silvia Tabano and Carcangiu, {Maria Luisa} and Paola Riva and Monica Miozzo and Siranoush Manoukian",
year = "2017",
month = "2",
day = "1",
doi = "10.1371/journal.pone.0171663",
language = "English",
volume = "12",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "2",

}

TY - JOUR

T1 - Revertant mosaicism for family mutations is not observed in BRCA1/2 phenocopies

AU - Azzollini, Jacopo

AU - Pesenti, Chiara

AU - Ferrari, Luca

AU - Fontana, Laura

AU - Calvello, Mariarosaria

AU - Peissel, Bernard

AU - Portera, Giorgio

AU - Tabano, Silvia

AU - Carcangiu, Maria Luisa

AU - Riva, Paola

AU - Miozzo, Monica

AU - Manoukian, Siranoush

PY - 2017/2/1

Y1 - 2017/2/1

N2 - In BRCA1/2 families, early-onset breast cancer (BrCa) cases may be also observed among non-carrier relatives. These women are considered phenocopies and raise difficult counselling issues concerning the selection of the index case and the residual risks estimate in negative family members. Few studies investigated the presence of potential genetic susceptibility factors in phenocopies, mainly focussing on BrCa-associated single-nucleotide polymorphisms. We hypothesized that, as for other Mendelian diseases, a revertant somatic mosaicism, resulting from spontaneous correction of a pathogenic mutation, might occur also in BRCA pedigrees. A putative low-level mosaicism in phenocopies, which has never been investigated, might be the causal factor undetected by standard diagnostic testing. We selected 16 non-carriers BrCa-affected from 15 BRCA1/2 families, and investigated the presence of mosaicism through MALDI-TOF mass spectrometry. The analyses were performed on available tumour samples (7 cases), blood leukocytes, buccal mucosa and urine samples (2 cases) or on blood only (7 cases). In one family (n.8), real-time PCR was also performed to analyse the phenocopy and her healthy parents. On the 16 phenocopies we did not detect the family mutations neither in the tumour, expected to display the highest mutation frequency, nor in the other analysed tissues. In family 8, all the genotyping assays did not detect mosaicism in the phenocopy or her healthy parents, supporting the hypothesis of a de novo occurrence of the BRCA2 mutation identified in the proband. These results suggest that somatic mosaicism is not likely to be a common phenomenon in BRCA1/2 families. As our families fulfilled high-risk selection criteria, other genetic factors might be responsible for most of these cases and have a significant impact on risk assessment in BRCA1/2 families. Finally, we found a de novo BRCA2 mutation, suggesting that, although rare, this event should be taken into account in the evaluation of high-risk families.

AB - In BRCA1/2 families, early-onset breast cancer (BrCa) cases may be also observed among non-carrier relatives. These women are considered phenocopies and raise difficult counselling issues concerning the selection of the index case and the residual risks estimate in negative family members. Few studies investigated the presence of potential genetic susceptibility factors in phenocopies, mainly focussing on BrCa-associated single-nucleotide polymorphisms. We hypothesized that, as for other Mendelian diseases, a revertant somatic mosaicism, resulting from spontaneous correction of a pathogenic mutation, might occur also in BRCA pedigrees. A putative low-level mosaicism in phenocopies, which has never been investigated, might be the causal factor undetected by standard diagnostic testing. We selected 16 non-carriers BrCa-affected from 15 BRCA1/2 families, and investigated the presence of mosaicism through MALDI-TOF mass spectrometry. The analyses were performed on available tumour samples (7 cases), blood leukocytes, buccal mucosa and urine samples (2 cases) or on blood only (7 cases). In one family (n.8), real-time PCR was also performed to analyse the phenocopy and her healthy parents. On the 16 phenocopies we did not detect the family mutations neither in the tumour, expected to display the highest mutation frequency, nor in the other analysed tissues. In family 8, all the genotyping assays did not detect mosaicism in the phenocopy or her healthy parents, supporting the hypothesis of a de novo occurrence of the BRCA2 mutation identified in the proband. These results suggest that somatic mosaicism is not likely to be a common phenomenon in BRCA1/2 families. As our families fulfilled high-risk selection criteria, other genetic factors might be responsible for most of these cases and have a significant impact on risk assessment in BRCA1/2 families. Finally, we found a de novo BRCA2 mutation, suggesting that, although rare, this event should be taken into account in the evaluation of high-risk families.

UR - http://www.scopus.com/inward/record.url?scp=85012979477&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85012979477&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0171663

DO - 10.1371/journal.pone.0171663

M3 - Article

VL - 12

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 2

M1 - e0171663

ER -